Publicacions en què col·labora amb Ana Martínez (19)

2017

  1. Biological and Pharmacological Characterization of Benzothiazole-Based CK-1δ Inhibitors in Models of Parkinson's Disease

    ACS Omega, Vol. 2, Núm. 8, pp. 5215-5220

  2. Pharmacological tools based on imidazole scaffold proved the utility of PDE10A inhibitors for Parkinson's disease

    Future Medicinal Chemistry, Vol. 9, Núm. 8, pp. 731-748

  3. Phosphodiesterase7 Inhibition Activates Adult Neurogenesis in Hippocampus and Subventricular Zone In Vitro and In Vivo

    Stem Cells, Vol. 35, Núm. 2, pp. 458-472

  4. Subtly Modulating Glycogen Synthase Kinase 3 β: Allosteric Inhibitor Development and Their Potential for the Treatment of Chronic Diseases

    Journal of Medicinal Chemistry, Vol. 60, Núm. 12, pp. 4983-5001

2016

  1. Small GSK-3 Inhibitor shows efficacy in a motor neuron disease murine model modulating autophagy

    PLoS ONE, Vol. 11, Núm. 9

2015

  1. Morphometric and neurochemical alterations found in l-BMAA treated rats

    Environmental Toxicology and Pharmacology, Vol. 39, Núm. 3, pp. 1232-1245

  2. PDE7 inhibitor TC3.6 ameliorates symptomatology in a model of primary progressive multiple sclerosis

    British Journal of Pharmacology, Vol. 172, Núm. 17, pp. 4277-4290

  3. Phosphodiesterase 7 inhibition induces dopaminergic neurogenesis in hemiparkinsonian rats

    Stem Cells Translational Medicine, Vol. 4, Núm. 6, pp. 564-575

  4. Silencing phosphodiesterase 7B gene by lentiviral-shRNA interference attenuates neurodegeneration and motor deficits in hemiparkinsonian mice

    Neurobiology of Aging, Vol. 36, Núm. 2, pp. 1160-1173

2014

  1. Crosstalk between phosphodiesterase 7 and glycogen synthase kinase-3: Two relevant therapeutic targets for neurological disorders

    ACS Chemical Neuroscience, Vol. 5, Núm. 3, pp. 194-204

  2. Modulation of cAMP-specific PDE without emetogenic activity: New sulfide-like PDE7 inhibitors

    Journal of Medicinal Chemistry, Vol. 57, Núm. 20, pp. 8590-8607

2013

  1. Glycogen synthase kinase-3 inhibitors as potent therapeutic agents for the treatment of Parkinson disease

    ACS Chemical Neuroscience, Vol. 4, Núm. 2, pp. 350-360

2012

  1. 5-Imino-1,2,4-thiadiazoles: First small molecules As substrate competitive inhibitors of glycogen synthase kinase 3

    Journal of Medicinal Chemistry, Vol. 55, Núm. 4, pp. 1645-1661

  2. Effect of phosphodiesterase 7 (PDE7) inhibitors in experimental autoimmune encephalomyelitis mice. Discovery of a new chemically diverse family of compounds

    Journal of Medicinal Chemistry, Vol. 55, Núm. 7, pp. 3274-3284

  3. Glycogen synthase kinase 3 inhibition promotes adult hippocampal neurogenesis in vitro and in vivo

    ACS Chemical Neuroscience, Vol. 3, Núm. 11, pp. 963-971

  4. The new iminothiadiazole derivative VP1.14 ameliorates hippocampal damage after an excitotoxic injury

    Journal of Neurochemistry, Vol. 122, Núm. 6, pp. 1193-1202

2011

  1. Phosphodiesterase 7 inhibition preserves dopaminergic neurons in cellular and rodent models of Parkinson disease

    PLoS ONE, Vol. 6, Núm. 2

2009

  1. Anticonvulsant and neuroprotective effects of the novel calcium antagonist NP04634 on kainic acid-induced seizures in rats

    Journal of Neuroscience Research, Vol. 87, Núm. 16, pp. 3687-3696

2007

  1. NP031112, a Thiadiazolidinone compound, prevents inflammation and neurodegeneration under excitotoxic conditions: Potential therapeutic role in brain disorders

    Journal of Neuroscience, Vol. 27, Núm. 21, pp. 5766-5776